All News
New EULAR/ACR Classification Criteria for Adult and Juvenile Myositis
The European League Against Rheumatism and the American College of Rheumatology (EULAR/ACR) have developed classification criteria for idiopathic inflammatory myopathies (IIM) based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% ad
Read ArticleDeath Rates from Lupus Remain Disproportionately High
The Annals of Internal Medicine reports that despite improving trends in mortality, death rates from systematic lupus erythematosus (lupus) remain high compared to those in the general population, and disparities persist between subpopulations and geographic regions. Underreporting of lupus on death certificates may have resulted in underestimates of mortality rates.
Read ArticleNecroptosis Drives Netosis and ANCA-Associated Vasculitis
PNAS reports that ANCA induced neutrophil activation, generation of neutrophil extracellular traps (NETS), and vasculitis are regulated by necroptosis. Using inhibitors of necroptosis-inducing kinases they were able to prevent ANCA associated vasculitis (AAV) in animal models.
Read ArticleBSR Guidelines on Lupus Management
In the UK, NICE has accredited the British Society of Rheumatology (BSR) to develop a guidance document on the management of systemic lupus erythematosus in adults. The last published guidelines for lupus were published in 2008 by EULAR and in 2012 by the ACR.
Read ArticleThe RheumNow Week in Review - 6 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.
Read ArticlePatterns of Biologic Use During Autoimmune Pregnancy
While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.
Read ArticleIBD Associated with Increased risk of Autoimmune and Inflammatory Diseases
A registry based study has shown higher rates of immune mediated diseases (IMD) in patients with inflammatory bowel disease (IBD).
Read ArticlePrimary Sjögren's Syndrome Guideline from the British Society for Rheumatology
The British Society of Rheumatology (BSR) has been accredited by NICE to develop a guidance document for the management of primary Sjögren's Syndrome intended for rheumatologists, general physicians, general practitioners, specialist nurses and other specialists (e.g.
Read Article29 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.
Read ArticleIsolated SS-B Not Associated with Connective Tissue Disease
A one-year prospective study of 624 patients undergoing autoantibody testing for anti-SS-A and/or anti-SS-B autoantibodies finds that isolated anti-SS-B autoantibodies was not associated with features or the diagnosis of any specific connective tissue diseases (CTD).
Read Article22 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses survey results on membranous nephritis and patient perceptions of steroids, nonadherence, celebrity arthritis and IgG4 treatment.
Read ArticleRituximab Efficacy in IgG4 Related Disease
PLOS reports greater than 90% efficacy when rituximab (RTX) is used to treat patients with IgG4-related disease (IgG4-RD).
Read ArticleHalf of Takayasu's Arteritis Relapse
A French retrospective study of 318 Takayasu's arteritis (TA) patients shows that 50% of patients will relapse and experience a vascular complication ≤10 years from diagnosis.
Read Article15 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.
Read ArticlePast Infection, Lung Disease Raise Risk for Myopathy
Infections and noninfectious pulmonary disease were associated with an increased risk for idiopathic inflammatory myopathies (IIM), a Swedish study found.
Read ArticleIdiopathic Inflammatory Myopathy Quadruples Death Risk
A Swedish population-based study found a nearly fourfold greater risk of all-cause mortality in idiopathic inflammatory myopathy (IIM) patients compared with the general population.
Read ArticleShingles Vaccine Studies in A&R
The current issue of Arthritis & Rheumatology features an editorial and two novel articles on the herpes zoster vaccine.
Read ArticleThe RheumNow Week in Review – 18 August 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com.
Read ArticleDuration of Azathioprine Maintenance in AAV Does Not Alter Relapse Rates
A European multicentre study examined whether the duration of azathioprine (AZA) maintenance therapy in ANCA-associated vasculitis patients would influence the relapse rate during long-term follow-up.
Read ArticleMycophenolate and Steroids in Neuropsychiatric Lupus
Beyond diagnosis, management of neuropsychiatric lupus (NPSLE) can be challenging. Moreover, there are scant studies addressing optimal management. In this issue of Clinical Rheumatology, researchers show the efficacy of mycophenolate mofetil (MMF) and deflazacort in NPSLE.
Read Article